Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-10-15 | May — Appointment of Dror Bashan as our new President & Chief Executive Officer |
| 2020-04-15 | Dror Bashan. Mr. Bashan has served as our President and Chief Executive Officer and as our director since June 2019. ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2019. ... Dror Bashan is not listed in the non-employee directors compensation table. |
| 2021-06-04 | Dror Bashan. Mr. Bashan has served as our President and Chief Executive Officer and as our director since June 2019. ... Summary Compensation Table shows total compensation of $1,341,952 for 2020. ... He is President and Chief Executive Officer. |
| 2021-09-30 | Dror Bashan, our President and Chief Executive Officer |
| 2022-04-29 | Dror Bashan. Mr. Bashan has served as our President and Chief Executive Officer and as our director since June 2019. He has over 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd (“Teva”). (NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva’s Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University and an MBA from the Tel Aviv University. |
| 2023-05-18 | Dror Bashan. Mr. Bashan has served as our President and Chief Executive Officer and as our director since June 2019. He has over 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health industries. |
| 2024-04-29 | Dror Bashan. Mr. Bashan has served as our President and Chief Executive Officer and as our director since June 2019. ... The Board of Directors recommends that you vote as follows: “FOR” the election or re-election of all director nominees named in “Proposal 1: Election of Directors.” ... The following table sets forth information, as of April 29, 2024, regarding beneficial ownership of our common stock: ... Dror Bashan (2) Consists of 132,516 outstanding shares of our common stock, 1,746,422 outstanding restricted shares of our common stock that are not subject to forfeiture within 60 days of April 29, 2024, 402,996 outstanding restricted shares of our common stock that are subject to forfeiture as of April 29, 2024 and 488,125 shares of our common stock issuable upon exercise of outstanding options within 60 days of April 29, 2024. ... Mr. Bashan has served as our President and Chief Executive Officer and as our director since June 2019. ... Compensation of Directors ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2023. ... Dror Bashan is an employee director and does not receive separate director compensation. |
Data sourced from SEC filings. Last updated: 2026-02-08